Julie Patterson, PharmD, PhD, senior director of research at the National Pharmaceutical Council, spoke to the ways in which possible unintended effects of the Inflation Reduction Act of 2022 (IRA) could impact patients.
Julie Patterson, PharmD, PhD, senior director of research at the National Pharmaceutical Council, spoke to the ways in which possible unintended effects of the Inflation Reduction Act of 2022 (IRA) could impact patients.
Patterson and colleagues authored a study published in the February issue of The American Journal of Managed Care® (AJMC®), "Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications," which details how the IRA could have unintended consequences on small molecule drug research and development.
In another video, Patterson discussed the study's findings and what they could mean for pharmaceutical innovation.
Transcript
How might the unintended consequences of the IRA impact the pharmaceutical industry and patients?
I'm so glad you asked about the potential unintended consequences of the IRA on patients. In the case of the first unintended consequence, we discussed seeing a delay in new launches. That would mean patients may have to wait longer to get access to new medicines.
In the case of the second unintended consequence we discussed, which is in the reduction of incentives to conduct clinical research needed to pursue subsequent indications, patients may see fewer diseases getting new treatment options approved. These approvals not only provide high-quality evidence on the drug's safety and effectiveness in new populations, but they're also often needed for insurers to cover drugs without access barriers for patients.
Other research showed that another potential unintended consequence of the IRA is related to patient access to the selected drugs after prices set by the government go into effect. Given the role of drug rebates and plan coverage decisions, insurers may be incentivized to restrict access for the selected drugs if nonselected drugs in the same class retain flexibility for higher rebates.
Right now, seniors have excellent access and experience few utilization management barriers—things like step therapy and prior authorization—to most of the first 10 drugs selected, but that may change. Increased utilization management requirements, which are likely in response to the IRA, could reduce patient access—exactly the opposite of what the program intends to do. That's why ensuring the patient perspective is incorporated into both the implementation process as well as the ongoing evaluation of the law's unintended consequences is so critical.
A new federal rule will enable thousands of immigrants in the Deferred Action for Childhood Arrivals (DACA) program to obtain health care through the Affordable Care Act; a forthcoming CMS rule is expected to lower home-based care wait times and raise caregiver wages; the HHS Office for Civil Rights has finalized 2 rules that strengthen the ACA’s health care discrimination ban.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Shelly Lanning on How Employers Can Reduce Costs by Bridging Gaps in Women's Health Care
May 3rd 2024In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More